Trial Profile
Randomized, Double-blind, Placebo-controlled trial on Reduced Coenzyme Q10 in Parkinson Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Ubidecarenone (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 03 May 2012 Company (Kaneka) added to associations field as reported by University Hospital Medical Information Network - Japan
- 03 May 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan
- 23 Mar 2012 New trial record